David Berman, MD, PhD, discusses signs of dose-dependent viral control and reduction in active HIV reservoir in Phase 1/2 STRIVE trial data.
David Berman, MD, PhD
Advertisement
Executive Vice President of Research and Development at Immunocore.
Articles by David Berman, MD, PhD
Advertisement
Latest Updated Articles
Immunocore Reports Some PWH Achieve Viral Control and Dose-Dependent Active HIV Reservoir Reduction in IMC-M113V TrialPublished: March 17th 2025 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
CDC's Latest Hepatitis B Vaccine Guidance Serves as Example for Future Federal Vaccine Policy
2
Growing International Evidence Suggests Emerging Metallo-β-Lactamase Therapy Could Benefit US Clinicians
3
Addressing the Three Pillars of PPE in Caring for Patients with High-Consequence Infectious Disease
4
Vigilance, Training, and Funding are Key for Outbreak and Pandemic Biopreparedness
5